PBM and drug pricing regulation will continue to be hot topics at the state level after several years of busy lawmaking, experts predict, even as PBM reforms appear stalled in Congress. They predict that more states than ever will continue to embrace or pursue policies like drug affordability review boards.
Key Takeaways
-
Over 100 drug pricing bills are under consideration in 29 states, much of it based on NASHP model legislation.
-
ERISA limits the impact of state affordability boards in the self-funded commercial market
“I do think the momentum is still strong, because states have the ability to do a lot more,” Kate Sikora, associate principal at Avalere Health, tells AIS Health, a division of MMIT. “Federal bills typically get a little bit watered down by the time they actually pass
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?